Global Aptamers Market to Reach USD 4.38 Billion by 2031 Amid Diagnostic and Therapeutic Innovation
San Diego, 4 June 2025 – Clearview Market Insights (CVMI) projects that the global aptamers market will grow from USD 1.52 billion in 2024 to USD 4.38 billion by 2031, achieving a compound annual growth rate (CAGR) of 16.3 percent. This strong outlook is supported by accelerating adoption in diagnostics, the rise of nucleic-acid therapeutics, and technological breakthroughs in aptamer discovery and modification.
"Aptamers offer a next-generation
alternative to antibodies across diagnostics, therapeutics, and biosensors,”
said Dr. Nicole Haider, senior molecular biology analyst at CVMI. “With
AI-driven SELEX, nanotechnology convergence, and biosafety-grade modifications,
aptamers are stepping into the biotech mainstream."
Request Sample @ https://clearviewmarketinsights.com/report-details/global-aptamers-market/
Key Numbers
- 2024
Market Value: USD 1.52 billion
- 2031
Market Value: USD 4.38 billion
- Seven-Year
CAGR: 16.3 percent
- DNA
Aptamers Share (2024): 48%
- North
America Market Share: 44%
Market Drivers
- Oncology
and infectious disease diagnostics
- Chemical
versatility and low immunogenicity
- Growth
in AI and high-throughput aptamer screening
- Strong
research pipelines in targeted delivery and biosensors
Company Highlights
- SomaLogic expanded proteomic applications to over 7,000 protein targets.
- Base
Pair Biotechnologies launched AI discovery tools for aptamer
affinity profiling.
- Aptamer
Group formed alliances with cell therapy
developers.
- NeoVentures deployed aptamer-based rapid test kits in food safety and
agriculture.
Regional Insights
- North
America: Leads in therapeutic R&D and
diagnostics adoption.
- Asia-Pacific: Fastest-growing region with rising investment in precision
medicine.
- Europe: Focused on academic collaborations and diagnostic biosensor
validation.
- LATAM
& MEA: Opportunities emerging in food safety
and portable diagnostics.
2024–2025 Milestones
Quarter |
Event |
Outcome |
Q1 2024 |
Base Pair debuts AI SELEX tool |
Shortens lead identification
by 35% |
Q2 2024 |
WHO trials aptamer diagnostics for dengue |
Positive early results in 3 countries |
Q3 2024 |
SomaLogic expands SOMAscan
diagnostic use |
Validated for cardiac
biomarkers |
Q1 2025 |
Aptamer Group signs CAR-T targeting partnership |
Therapeutic aptamer market entry confirmed |
For more
insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and
consulting firm providing in-depth industry analysis and strategic
recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
Comments
Post a Comment